Osteoporosis International最新文献

Hip fracture is a public health problem recognized worldwide and a potentially catastrophic threat for older persons, even carrying a demonstrated excess of mortality. Handgrip strength (HGS) has been identified as a predictor of different outcomes (mainly mortality and disability) in several groups with hip fracture.

Purpose: The aim of this study was to determine the association between low HGS and 1-year mortality in a cohort of older patients over 60 years old with fragility hip fractures who underwent surgery in the Colombian Andes Mountains.

Methods: A total of 126 patients (median age 81 years, women 77%) with a fragility hip fracture during 2019-2020 were admitted to a tertiary care hospital. HGS was measured using dynamometry upon admission, and data about sociodemographic, clinical and functional, laboratory, and surgical intervention variables were collected. They were followed up until discharge. Those who survived were contacted by telephone at one, three, and 12 months. Bivariate, multivariate, and Kaplan-Meier analyses with survival curves were performed.

Results: The prevalence of low HGS in the cohort was 71.4%, and these patients were older, had poorer functional and cognitive status, higher comorbidity, higher surgical risk, time from admission to surgery > 72 h, lower hemoglobin and albumin values, and greater intra-hospital mortality at one and three months (all p < 0.01). Mortality at one year in in patients with low HGS was 42.2% and 8.3% in those with normal HGS, with a statistically significant difference (p = 0.000). In the multivariate analysis, low HGS and dependent gait measured by Functional Ambulation Classification (FAC) were the factors affecting postoperative 1-year mortality in older adults with hip fractures.

Conclusion: In this study of older people with fragility hip fractures, low HGS and dependent gait were independent predictive markers of 1-year mortality.

Both osteoporosis and idiopathic normal pressure hydrocephalus may increase the risk of falls and fractures. This study showed that osteoporosis is more common in older patients with iNPH. It is important to raise awareness of osteoporosis in older patients with iNPH to prevent adverse health consequences.

Purpose: Idiopathic normal pressure hydrocephalus (iNPH), a potentially reversible condition with timely intervention, may cause cognitive impairment, balance and gait disturbance, and urinary incontinence in advanced age. Osteoporosis is a progressive metabolic bone disease that increases bone fragility in older adults. Both conditions may lead to falls and fractures. Therefore, this study aims to investigate osteoporosis in older adults with iNPH.

Methods: A total of 64 patients diagnosed with iNPH and 458 participants in the control group were included in the study. Demographic and clinical characteristics, including age, sex, comorbidities, laboratory findings, and comprehensive geriatric assessment parameters, were recorded. Osteoporosis was defined according to the WHO classification. The relationship between osteoporosis and iNPH was assessed with regression analysis.

Results: The mean age was higher in the iNPH group than in the control group (79.91 ± 6.36 vs 75.86 ± 6.51 years, p < 0.001). The frequency of female patients was higher in the control group than in the iNPH group (81% vs 70.3%, p = 0.046). The osteoporosis frequency was higher in the iNPH group than in the controls (51.6% vs 32.1%, p = 0.002). Adjusted for age and gender, iNPH was associated with osteoporosis (odds ratio (OR), 1.750; confidence interval (CI) 95%, 1.002-3.054; p = 0.049).

Conclusions: This study showed that osteoporosis is more common in older patients with iNPH. Therefore, screening and treatment of osteoporosis in these individuals is crucial to avoid adverse health outcomes such as fractures.

Osteonecrosis of the jaw (ONJ) is an adverse effect of antiresorptives. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use. Absolute risks remained low (~ 0.05% after 5 years) and diminished after discontinuation.

Purpose: Osteonecrosis of the jaw (ONJ) is a rare adverse effect of antiresorptive drug use; however, the magnitude of risk in osteoporosis patients has not been clearly described.

Methods: We conducted a cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in United Kingdom Clinical Practice Research Datalink (CPRD) Aurum. We followed patients from first osteoporosis treatment until first of osteonecrosis diagnosis, age 90, record end, or other prespecified censoring event, and accumulated person-time by osteoporosis treatment. ONJ cases were selected from CPRD Aurum and linked Hospital Episode Statistics data using an algorithm and manual review. We estimated incidence rates (IR) of ONJ by current treatment type and post discontinuation. We conducted a nested case-control analysis to further describe risk by cumulative dose and duration of antiresorptive therapies.

Results: Among 467,654 eligible patients, there were 208 ONJ cases. IR among patients currently treated with antiresorptives (primarily alendronate) was 1.2 (95% confidence interval [CI] 1.0-1.4) per 10,000 person-years. Compared with past use of antiresorptives, odds ratios of ONJ were 3.0 (95% CI 1.5-5.7) after 2-3 years of treatment and 8.1 (95% CI 4.4-15) after 10 years. However, absolute risks remained low (~ 0.05% after 5 years and ~ 0.18% after 10 years) and elevated risks diminished to near zero within 6 to 9 months of discontinuation.

Conclusion: Risk of ONJ increased after 2-3 years of treatment with antiresorptives; however, the absolute risk was low and returned to baseline shortly after treatment discontinuation.

The purpose of this study was to determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic vertebral fracture. Of patients, 15.5% underwent subsequent vertebral augmentation. The patient's comorbidities are strongly associated with risk of subsequent treatment.

Purpose: To determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic and disabling vertebral fracture.

Methods: We conducted a retrospective cohort study using commercial insurance claims data (Optum's de-identified Clinformatics® Data Mart Database). Adult patients who underwent subsequent treatment for vertebral fracture within 24 months of initial balloon kyphoplasty (BKP) or vertebroplasty (VP) were classified into "subsequent treatment" or "no subsequent treatment" cohorts. Survival analysis was applied to investigate the effect of risk factors on subsequent treatment.

Results: Between 1 January 2008 and 30 June 2020, a total of 32,513 adult patients underwent a BKP/VP procedure following a diagnosis of vertebral compression fracture in the preceding 12 months. Five thousand thirty-five patients (15.5%) underwent a subsequent BKP/VP treatment within 2 years; 90% had a single fracture level treated. An increased hazard of subsequent treatment was associated with a number of fractures treated at initial BKP/VP (≥ 4 levels, adjusted hazard ratio (AHR) 1.68 (95% CI 1.24-2.26); steroid use, AHR 1.9 (95% CI 1.31-1.48); Elixhauser Comorbidity Index ≥ 4, AHR 1.44 (95% CI 1.17-1.77); and multiple myeloma, AHR 1.31 (95% CI 1.13-1.53)). Age < 70 years was associated with reduced hazard of subsequent treatment (AHR 0.81, 95% CI 0.74-0.89).

Conclusions: One in seven patients underwent subsequent treatment for vertebral fracture after initial vertebral augmentation. Baseline patient characteristics were associated with increased risk of subsequent fracture within 2 years, suggesting that a patient's natural history is strongly associated with risk of subsequent treatment rather than the initial surgical procedure itself.

This study aimed to validate the correlation between volumetric bone mineral density in the cervicothoracic and lumbar spine using measurements from opportunistic CT scans. The bone density assessment proved feasible, allowing us to propose optimal cut-off values for diagnosing osteoporosis and predicting vertebral fractures in the cervical and thoracic spine.

Objectives: To investigate the performance of cervicothoracic volumetric bone mineral density (vBMD), obtained through opportunistic quantitative computed tomography (QCT), in discriminating patients with/without osteoporosis and with/without vertebral fractures (VFs), using lumbar vBMD as the reference.

Methods: Three hundred twenty-five patients (65.3 ± 19.2 years, 140 women) with routine non-contrast or contrast-enhanced multi-detector CT (MDCT) scans were included. Trabecular vBMD was automatically extracted from each vertebra using a convolutional neural network (CNN)-based framework (SpineQ software v1.0) with asynchronous calibration and contrast phase correction. The correlations of vBMD between each vertebra spanning C2-T12 and the averaged lumbar spine (L1-L3, or L4 and L5) vBMD values were analyzed, considering fracture status and degeneration. Vertebra-specific linear regression equations were used to approximate lumbar vBMD at the cervicothoracic spine.

Results: Cervicothoracic vBMD correlated well with lumbar vBMD (r = 0.79), with significant improvement after excluding degenerated vertebrae (p < 0.05; r = 0.89), except for C7-T3 and T9. Cervical (AUC = 0.94) and thoracic vBMD (AUC = 0.97) showed strong discriminatory ability for osteoporosis (vBMD < 80 mg/cm³). Excluding degenerated vertebrae at the cervical spine increased the AUC to 0.97. Cervical and thoracic vBMD (AUC = 0.74, AUC = 0.72) were comparable to lumbar vBMD (AUC = 0.72) in differentiating patients with and without prevalent VFs. Trabecular vBMD < 190 mg/cm³ for the cervical spine and < 100 mg/cm³ for the thoracic spine were potential indicators of osteoporosis, similar to < 80 mg/cm³ at the lumbar spine.

Conclusion: Cervicothoracic vBMD may allow for determination of osteoporosis and prediction of VFs.

Osteoporosis is a prevalent condition that significantly increases fracture risk, particularly in the elderly population. Despite its widespread occurrence, osteoporosis is often underdiagnosed and inadequately managed. Traditional diagnostic methods, such as dual-energy X-ray absorptiometry (DXA), have limitations in terms of accessibility and accuracy, necessitating exploration of alternative diagnostic approaches.This review aims to evaluate the diagnostic potential of Hounsfield Unit (HU) values derived from abdominal computed tomography (CT) scans, specifically focusing on the trabecular bone of the lumbar spine, for osteoporosis assessment in individuals aged 65 and older. The review seeks to assess the sensitivity, specificity, and overall diagnostic performance of HU values in distinguishing between normal bone density, osteopenia, and osteoporosis, and to identify areas for further investigation to establish standardized diagnostic criteria.This review compiles existing studies on the use of HU values from abdominal CT scans for osteoporosis diagnosis. It examines the relationship between HU values and DXA T-scores, analyzes optimal HU thresholds for classifying bone density categories, and explores the potential of CT scans as a viable alternative to DXA.The findings indicate that HU values from abdominal CT scans show strong correlations with DXA T-scores, suggesting a promising diagnostic tool for assessing bone density and quality. HU values have demonstrated the ability to differentiate between osteopenia, osteoporosis, and normal bone density, with varying sensitivity and specificity depending on the established HU threshold. CT scans are identified as a scalable, cost-effective alternative to DXA, with the added benefit of utilizing routine abdominal CT scans, which are often conducted for other clinical reasons, thereby reducing additional costs and radiation exposure.HU values derived from abdominal CT scans represent a promising approach for osteoporosis screening, offering a potential solution for routine, cost-effective, and accurate diagnosis, especially in older adults. However, there is a need for standardized HU thresholds and further research to refine diagnostic criteria and enhance the accuracy of osteoporosis detection. Establishing standardized guidelines would improve diagnostic consistency and facilitate early intervention, potentially improving patient outcomes and reducing healthcare burdens.

This study examined the impact of thiazide and RAAS antihypertensive medications vs DHP-RAAS medications on fracture risk. The close alignment of such settings with clinical use, combined with the potential bone benefits of ACEis and ARBs, provides enhanced accuracy in bone health evidence.

Purpose: To determine whether thiazides, combined with either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), offer bone-protective benefits compared with dihydropyridine (DHP) drugs combined with ACEi or ARB.

Methods: This retrospective cohort study was conducted on the US Collaborative Network from the TriNetX database on March 5th, 2024. It included hypertensive ACEi or ARB users under thiazide or DHP drug treatments spanning from January 1st, 2015, to December 31st, 2022, with exclusion criteria applied. The primary outcome is a composite typical osteoporotic fracture (TOPF). Kaplan Meier analyses were performed after 1:1 propensity-score matching (PSM) with a 5-year follow-up. Besides investigating fracture-related outcomes in thiazide-ACEi/ARB and DHP-ACEi/ARB users, this study explores whether the effects differ between ACEi and ARB users. Subgroup analyses were also performed, and the heterogeneity among the results was assessed using Cochran's Q-tests.

Results: Post-PSM results yield 54,240 patients per cohort in the primary analysis, aging 61.5 ± 12.2 versus 61.4 ± 13.7 (thiazide-ACEi/ARB versus DHP-ACEi/ARB) with predominantly white ethnicity. Thiazide-ACEi/ARB users exhibit lower TOPF risk than DHP-ACEi/ARB users (hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.61-0.70), and such benefits from thiazides are similar between ACEi and ARB users (ACEi: HR = 0.69; ARB: HR = 0.67, Cochran's Q-test p-value = 0.78). Additionally, the effects of thiazides reveal significant heterogeneity between patients with and without inflammatory polyarthropathy (ICD-10, M05-M14) and benzodiazepine usage (Cochran's Q-test p-value = 0.01, 0.04).

Conclusion: Thiazides are associated with lower risks of typical osteoporotic fractures compared to DHP drugs in patients treated with ACEi or ARB, while such benefits may diminish in those with a diagnosis of inflammatory polyarthropathy and benzodiazepine usage.

A cost-effectiveness analysis of FRAX® intervention thresholds (ITs) in Indian women over 50 years indicated that generic alendronate was cost-effective for age-dependent major osteoporotic fracture (MOF) ITs and hip fracture (HF) ITs starting at ages 60 and 65 years for full and real-world adherence, respectively. Alendronate was cost-effective at fixed MOF IT of 14% and HF IT of 3.5%, regardless of age.

Purpose: Osteoporosis represents a significant public health challenge in India, with an increasing economic burden due to the aging population. This study evaluated the cost-effectiveness of using fracture risk assessment tool (FRAX®)-based intervention thresholds (ITs) for managing osteoporosis with generic alendronate in Indian women.

Methods: A Markov microsimulation model, adapted to the Indian healthcare context, was used to simulate the costs and quality-adjusted life years (QALYs) associated with different treatment strategies. The one-time gross domestic product (GDP) per capita (estimated at INR 1,97,468/QALY gained) was used as the cost-effectiveness threshold.

Results: The model revealed that generic alendronate is cost-effective for major osteoporotic fracture (MOF) ITs beginning at age 60 years with full adherence-incremental cost-effectiveness ratio (ICER) of INR 102,151 per QALY gained, and age 65 with real-world adherence-ICER of INR 28,203 per QALY gained (conversion rate used is 1 US dollar (USD) = INR 83.97 and 1 EURO = INR 92.70). Hip fracture (HF) ITs showed similar cost-effectiveness at ages 60 (ICER of INR 67,144) and was the dominant strategy (i.e., more QALYs for lower costs) at ≥ 65 years. Fixed ITs of 14% for MOF and 3.5% for HF proved cost-effective across all age groups (dominant strategy for ages ≥ 65 years). Limitations of our study include the reliance on fracture incidence data from Singaporean Indians and variability in fracture prevalence across India.

Conclusion: The results support the integration of FRAX®-based fixed ITs from the age of 50 years and age-based ones from the age of 65 years in India to optimize resource allocation and improve osteoporosis management.